Instructions for Authors 2016

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click here)

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Results given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   • The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal's policy.
   • they do not follow the instructions to authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2015): 64%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH. The IIAR is a member of UICC.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Effects of Targeted Proton Radiation on Spinal Cord in a Porcine Model: A Pilot Study. X.W. MAO, M.J. PECAUT, J.D. CAO, D.S. GRIDLEY (Loma Linda, CA, USA)
Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters. Y. MURAKAMI, A. KAWATA, S. ITO, T. KATAYAMA, S. FUJISAWA (Sakado, Saitama; Tokyo, Japan)
Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (Lübeck; Mannheim, Germany)
Implementation of a Functional Observation Battery for the Assessment of Postoperative Well being in Rats Subjected to Fimbria-Fornix Transection. L. MARSCHNER, E. WOGENSEN, J. MOGENSEN, K. ABELSON (Copenhagen, Denmark)
Decreased Numbers of CD57<sup>+</sup>CD3<sup>–</sup> Cells Identify Potential Inmate Immune Differences in Patients with Autism Spectrum Disorder. D. SINISCALCO, T. MIJATOVIC, E. BOSMANS, A. CIRILLO, P. KRUZLIJK, V.C. LOMBARDI, K. DE MEIRLEIR, N. ANTONUCCI (Naples; Caserta; Florence; Bari, Italy; Zellik; Brussels, Belgium; Brno, Czech Republic; Reno, NV, USA)
PEG-generated Surfaces Support Attachment and Growth of Cells In Vitro with No Additional Benefit for Micro-roughness in Sa (0.2-4 μm). O. JUNG, R. SMEETS, A. KOPP, D. PORCHETTA, P. HIESTER, M. HEILAND, R.E. FRIEDRICH, C. PRECHT, H. HANKEN, A. GRÖBE, P. HARTJEN (Hamburg; Aachen, Germany)
Suppressive Activity of Quercetin on Periostin Functions In Vitro. S. IRIE, M. KASHIWABARA, A. YAMADA, K. ASANO (Yokohama, Japan)
The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. P.P. SORDILLO, D.C. SORDILLO, L. HELSON (Quakertown, PA, USA)
Specific Antibodies to Staphylococcus aureus Biofilm Are Present in Serum from Pigs with Osteomyelitis. L.K. JENSEN, H.E. JENSEN, J. KOCH, T. BJARNSHOLT, S. EICKHARDT, M. SHIRTLIFF (Copenhagen, Denmark; Baltimore, MD, USA)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
**A Selection of Recent Articles**

Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma. X. LAI, S. CHEN (Indianapolis, IN, USA)

A Low-density Antigen Array for Detection of Disease-associated Autoantibodies in Human Plasma. R.I. SOMIARI, R. SUTPHEN, K. RENGANATHAN, S. RUSSELL, E. PASTWA, S.A. SOMIARI (Johnstown; Windber, PA; Tampa, FL, USA)

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma. T. DENYSENKO, L. ANNO-VAZZI, P. CASSONI, A. MELCARNE, M. MELLAI, D. SCHIFFER (Vercelli; Turin, Italy)

Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. M.K. DAS, R. ANDREASSEN, T.B. HAUGEN, K. FURU (Oslo, Norway)


Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells. M. PETROVIC, C. SIMILLION, P. KRUZLIK, J. SABO, M. HELLER (Kosice, Slovak Republic; Bern, Switzerland; Brno, Czech Republic)

Molecular Mechanisms of Bone Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORG, R. RÜGER (Penzberg, Germany)

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling. E. KJELDSEN (Aarhus, Denmark)

MTA1 Is Up-regulated in Colorectal Cancer and Is Inversely Correlated with Lymphatic Metastasis. J. LI, L. YE, P.-H. SUN, L. SATHERLEY, R. HARGEST, Z. ZHANG, W.G. JIANG (Cardiff, UK; Beijing, PR China)


Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. S. SUGIE, S. MUKAI, K. YAMASAKI, T. KAMIBEPPU, H. TSUKINO, T. KAMOTO (Miyazaki, Japan)

Delayed 5-Fluorouracil Toxicity with Uridine Triacetate in Patients with Dihydropyrimidine Dehydrogenase Deficiency. M.W. SAIF, R.B. DIASIO (Boston, MA; Rochester, MN, USA)
Clinical Significance of $^{18}$F-FDG-PET in Invasive Lobular Carcinoma. T. FUJII, R. YAJIMA, S. KUROZUMI, T. HIGUCHI, S. Oabayashi, H. TOKINIWA, R. NAGAOka, D. TAKATA, J. HORIGUCHI, H. KUWANO (Gunma, Japan) ................................................................. 5481

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission. M. KARAS, K. STEINEROVA, D. LYSAK, M. HRABETOVA, A. JUNGOVA, J. SRAMEK, P. JINDRA, J. POLIVKA, L. HOLUBEc (Plzen, Czech Republic) ............................................................... 5487

Low Mast Cell Density Predicts Poor Prognosis in Oral Squamous Cell Carcinoma and Reduces Survival in Head and Neck Squamous Cell Carcinoma. C.G. ATTRAMADAL, S. KUMAR, J. GAO, M.E. BOYSEN, T.S. HALSTENSEN, M. BRYNE (Oslo, Norway) ................................................................. 5499


Exploring the Use of Oropharyngeal Cancer Histology to Account for HPV Status in Population-based Studies. U.C. MEGWALU (Stanford, CA, USA) ................................................................. 5515

Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy. M. SAKAGUCHI, T. MAEBAYASHI, T. AIZAWA, N. ISHIBASHI, T. Saito (Tokyo, Japan) ................................................................. 5519

Deep Vein Thrombosis: An Independent Poor Prognosis Factor of Advanced Pancreatic Adenocarcinoma. M. LAMBERT, A. PLOQUIN, L. DECLERCK, A. DUHAMEL, S. MAKLHOUFI, A. TURPIN, S. TRUANT, M. HEBBAR (Lille, France) ................................................................. 5527

Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan. H. KITAMURA, A. TAKAHASHI, F. TAKEI, H. HOTTa, N. MIYAO, T. SHINDO, M. IGARASHI, H. TACHIKI, Y. KUNISHIMA, T. MURANAKA, M. SHIGYO, Y. IKEHATA, N. MASUMORI (Toyama; Hakodate; Sunagawa; Asahikawa; Muroran; Sapporo; Takikawa; Obhiro; Kushiro; Tomakomai, Japan) ................................................ 5531

Inflammation-based Prognostic Score in Patients with Living Donor Liver Transplantation for Hepatocellular Carcinoma. N. HARIMOTO, T. YOSHIZUMI, T. SHIMAGAKI, A. NAGATSU, T. MOMOTOMA, N. HARADA, H. OKABE, S. ICTOH, T. IKEGAMI, H. UCHIYAMA, Y. SOEJIMA, Y. MAEHARA (Fukuoka, Japan) ................................................ 5537

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma. N. LEMOINE, A. ADENIS, O. BOUCHE, A. DUHAMEL, A. HEURGUE, E. LETEURTRE, E. AMELA, J. SALLERON, M. HEBBAR (Lille; Reims, France) ................................................................. 5543

Bevacizumab Associated with Chemotherapy for Initially Non-resectable Liver Metastases from Colorectal Cancer: a Case-Control Study. M. ALT, S. TRUANT, T. RENAUD-VANTROYS, C. SEQUIER, A. DUHAMEL, M. EL AMRANY, A. TURPIN, S. MAKHLHOUFI, F.R. PRUVOT, M. HEBBAR (Lille, France) ................................................................. 5551

Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma. H. IWAMOTO, K. Izumi, Y. SHIMURA, A. NATSAGDORJ, A. MAOLAKE, Y. TAKEZAWA, T. NOHARA, K. SHIGEHERA, Y. KADONO, A. MIzOKAMI (Kanazawa, Japan) ................................................................. 5557

Radiation Pneumonitis Changes over Time after Stereotactic Body Radiation Therapy for Lung Tumors: Post-Treatment Cavity (Sunny-side-up Egg-like) Changes. T. MAEBAYASHI, N. ISHIBASHI, T. AIZAWA, M. SAKAGUCHI, T. SATO, J. KAWAMORI, Y. TANAKA (Tokyo; Kawasaki, Japan) ................................................................. 5563
Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice. H. KOYI, G. HILLERDAL, K.-G. KÖLBECK, D. BRODIN, P. LIV, E. BRANDÉN (Gävle; Stockholm, Sweden) .................................................. 5397


Analysis of Factors Associated with Weight Loss After Esophagectomy for Esophageal Cancer. H. KITAGAWA, T. NAMIKAWA, M. MUNEKAGE, K. FUJISAWA, E. MUNEKAGE, Y. KAWANISHI, M. KOBAYASHI, K. HANAZAKI (Nankoku, Japan) ............................................................................................ 5409


Anti-metastatic Effect of Short-term Postoperative Anticoagulation for Patients Undergoing Curative Resection of Colorectal Cancer. Y. YAMAOKA, M. IKEDA, M. IKENAGA, H. MURAKAMI, N. HARAGUCHI, M. MIYAKE, K. YAMAMOTO, T. ASAOKA, K. NISHIKAWA, A. MIYAMOTO, M. MIYAZAKI, M. HIRAO, S. NAKAMORI, M. SEKIMOTO (Osaka; Higashiosaka; Suita, Japan) .............. 5425

Clinical Impact of Stomach-partitioning Gastrojejunostomy with Braun Enteroenterostomy for Patients with Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer. T. ARIGAMI, Y. UENOSONO, S. ISHIGAMI, S. NAGAYOSHI, T. KITA, S. MORI, H. KURAHARA, K. MAEMURA, S. NATSUGOE (Kagoshima, Japan) .............................................................................................. 5431

CX43 Expression in Colonic Adenomas and Surrounding Mucosa Is a Marker of Malignant Potential. A. BIŠĆANIN, N. LJUBIČIĆ, M. BOBAN, D. BALIČEVIĆ, I. PAVIĆ, M.M. BIŠĆANIN, I. BUDIMIR, Z. DOROSULIC, M. DUVNIJAK (Zagreb; Opatija; Osijek, Croatia) .................................................................... 5437

Influence of Organ Invasion in Clinical Outcomes for Locally Advanced Rectal Cancer. F. DE FELICE, D. MUSIO, I. BENEVENTO, A. MAGNANTE, N. BULZONETTI, C. ROSELLA, V. TOMBOLINI (Rome, Italy) .............. 5443

miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer. M. SARLINÓVA, M. HALÁSA, D. MISTUŠA, L. MUSÁK, R. ILIEV, O. SLABÝ, J. MAŽUCHOVÁ, V. VALENTOVÁ, L. PLANK, E. HALÁSOVÁ (Martin, Slovak Republic; Brno, Czech Republic) .............. 5449


Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. D. RADES, D. SEIDL, B. WOLLENBERG, S.E. SCHILD, S.G. HAKIM (Lübeck, Germany; Scottsdale, AZ, USA) .................................................................................................................. 5463

A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies. S. JANSSEN, A. BAJROVIC, S.E. SCHILD, D. RADES (Lübeck; Hannover; Hamburg, Germany; Scottsdale, AZ, USA) .................................................................................................................. 5469


Contents continued on the preceding page
Clinical Studies


Neurofibromin Expression is Associated with Aggressive Disease and Poor Outcome in Colorectal Carcinoma. A. ELZAGHEID, F. EMAETIG, W. ELSAGHAYER, F. TORJMAN, M. LATTO, K. SYRJÄNEN, Y. COLLAN, S. PYRHÖNEN (Benghazi; Tripoli; Misurata, Libya; Turku, Finland; Barretos-SP, Brazil) ........................................ 5301

Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation. J. SHEN, C.-C. YEH, Q. WANG, I. GURVICH, A.B. SIEGEL, R.M. SANTELLA (New York, NY, USA; Taipei, Taiwan, ROC) .............................................................................................................................................. 5307

KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer. M. SIDERIS, J. MOORHEAD, S. DIAZ-CANO, I. BJARNASON, A. HAJI, S. PAPAGRIGORIADIS (London, UK) ................................................................. 5315

Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. K. KODA, H. MIYAUCHI, C. KOSUGI, T. KAIHO, N. TAKIGUCHI, S. KOBAYASHI, T. MARUYAMA, H. MATSUBARA (Chiba, Japan) .................................................................................................................................................................. 5325

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases. N. SHAVERDIAN, J. WANG, R. LEVIN-EPSTEIN, D. SCHAUE, P. KUPELIAN, P. LEE, I. YANG, T. KAPREALIAN (Los Angeles, CA, USA) ............................................................................................................................................................................................................. 5333


Vitamin D3 Treatment Influences PGE2 and TGFβ in Normal and Increased Breast Cancer Risk Women. W. QIN, M.F. HOLICK, W. SORESEN, C.R. WALKER, E.R. SAUTER (Tyler, TX; Boston, MA; Hartford, CT, USA) .................................................................................................................................................................................................. 5347

Prognostic Impact of Intraoperative Blood Loss in Liver Transplant Patients with Advanced Hepatocellular Carcinoma. A. KORNBERG, U. WITT, J. KORNBERG, G.O. CEYHAN, K. MUELLER, H. FRIESS, K. THRUM (Munich; Jena; Berlin, Germany) .................................................................................................................................................................................................. 5355

What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. Z. HILAL, B. SCHULTEIS, F. HARTMANN, A. DOGAN, C. CETIN, H. KRENTEL, S. SCHIERMEIER, C.B. TEMPFER (Bochum; Herne; Witten, Germany) .................................................................................................................................................................................................. 5365

The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer. M. ROSENDAHL, B.J. MOSGAARD, C. HØGDALL (Copenhagen, Denmark) .................................................................................................................................................................................................. 5373

Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. M. KOSKAS, J. DEPREEUW, S. MOENS, D. ANNIBALI, T. CUPPENS, P. MOERMAN, D. LAMBRCHETS, F. AMANT (Leuven, Belgium; Paris; Montigny-le-Bretonneux, France; Amsterdam, the Netherlands) .................................................................................................................................................................................................. 5381

Gut-associated Lymphoid Tissue (GALT) Carcinoma or Dome Carcinoma? C.A. RUBIO, P.T. SCHMIDT (Stockholm, Sweden) .................................................................................................................................................................................................. 5385

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy. A.R. WALDREP, E.J. AVERY, F.F. ROSE JR., M.V. MIDATHADA, J.A. TILFORD, H.-C. KOLBERG, M.R. HUTCHINS (Lincoln, NE, USA; Bottrop, Germany) .................................................................................................................................................................................................. 5389

Contents continued on the preceding page
Bongkrekic Acid as a Warburg Effect Modulator in Long-term Estradiol-deprived MCF-7 Breast Cancer Cells. S. TAKEDA, H. OKAZAKI, T. KUDO, K. KAKIZOE, T. HIMENO, K. MATSUMOTO, M. SHINDO, H. ARAMAKI (Hiroshima; Fukuoka; Kasuga, Japan) ................................................................. 5171


Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. M.C. KRIEGMAIR, M. BALK, R. WIRTZ, A. STEIDLER, C.-A. WEIS, J. BREYER, A. HARTMANN, C. BOLENZ, P. ERBEN (Mannheim; Köln; Regensburg; Erlangen; Ulm, Germany) .......... 5205

The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer. K. YAWATA, S. OSADA, T. TANAHASHI, S. MATSUI, Y. SASAKI, Y. TANAKA, N. OKUMURA, N. MATSUHASHI, T. TAKAHASHI, K. YAMAGUCHI, K. YOSHIDA (Gifu, Japan) ................................................................. 5215

Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment. T. VILSMAIER, B. RACK, A. KÖNIG, K. FRIESE, W. JANNI, U. JESCHKE, T. WEISSENBACHER, SUCCESS Study Group (Munich; Ulm, Germany) .......... 5227


β-Catenin Expression Regulates Cell Migration of Human Colonic Adenocarcinoma Cells Through Gelsolin. D. BACZYNSKA, I. BOMBIK, M. MALICKA-BŁASZKIEWICZ (Wroclaw, Poland) ................................................................. 5249

Runt-related Transcription Factor 1 (RUNX1/T) Suppresses Colorectal Cancer Cells Through Regulation of Cell Proliferation and Chemotherapeutic Drug Resistance. M. ALFAYEZ, R. VISHNUBALAJI, N.M. ALAJEZ (Riyadh, Kingdom of Saudi Arabia) ........................................................................................................................................................................................................................................................................................................................................ 5257

Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer. I.M. COBEC, I. SAS, L. PIRTEA, A.M. CIMPEAN, A.E. MOATAR, R.A. CAEȘU, M. RAICA (Timișoara, Romania; Heidelberg, Germany) ................................................................................................................................. 5265

Detection of Redox Imbalance in Normal Lymphocytes with Induced Mitochondrial Dysfunction – EPR Study. E. GEORGIEVA, Z. ZHELEV, I. AOKI, R. BAKALOVA, T. HIGASHI (Stara Zagora; Sofia, Bulgaria; Chiba, Japan) ......................................................................................................................................................................................................................................................................................................................... 5273


Fluorescence Imaging of Actin Fine Structure in Tumor Tissues Using SiR–Actin Staining. N.V. KLEMENTIEVA, I.B. SNOPOVA, N.N. PRODANETS, O.E. FURMAN, V.V. DUĐENKOVA, E.V. ZAGAYNOVA, K.A. LUKYANOV, A.S. MISHIN (Nizhny Novgorod; Moscow, Russian Federation) ........................................................................................................................................................................................................................................................................................................................................ 5287

Contents continued on the preceding page
Experimental Studies


Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment. J.V. MICHAEL, J.G.T. WURTZEL, L.E. GOLDFINGER (Philadelphia, PA, USA) ...................................................................................... 5053

Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition. J.S. IM, Y. PARK, B.M. LEE, H.S. KIM, S. YOON (Suwon, Republic of Korea) ...................................................................... 5063

Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats. D.R. WORLEY, R.J. HANSEN, L.A. WITTENBURG, L.S. CHUBB, D.L. GUSTAFSON (Fort Collins, CO, USA) ........................................................................................................................................ 5071

Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models. R. CHELLURI, T. CAZA, M.R. WOODFORD, J.E. REEDER, G. BRATSLAVSKY, T. BYLER (Syracuse; Rochester, NY, USA) ................................................................................................................................................ 5079

Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular Carcinoma. H.G. HASS, U. VOGEL, M. SCHEURLEN, J. JOBST (Scheidegg; Tuebingen; Wuerzburg; Reutlingen, Germany) ................................................................................. 5087

Ursolic Acid Suppresses Hepatitis B Virus X Protein-mediated Autophagy and Chemotherapeutic Drug Resistance. C.-D. CHANG, P.-Y. LIN, J.-L. HSU, W.-L. SHIH (Pingtung; Chiayi, Taiwan, ROC) .............. 5097


A Panel of Serum Biomarkers (GastroPanel®) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. K. SYRJÄNEN (Helsinki, Finland; Barretos, SP, Brazil) ................................................................................................................................................................................................................................................ 5133


Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance. S. SUZUKI, M. OKADA, K. KURAMOTO, H. TAKEDA, H. SAKAKI, H. WATARAI, T. SANOMACHI, S. SEINO, T. YOSHIKOA, C. KITANAKA (Yamagata, Japan) ............................................................................................................................................................................................................................................. 5153


Contents continued on the preceding page